Clinical trials · Texas
Rhabdomyosarcoma clinical trials in Texas
We’re tracking 12 recruiting rhabdomyosarcoma studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05304585RecruitingPhase 3
Chemo for children with early, low-risk fusion-negative rhabdomyosarcoma
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Fort Worth, TexasAges Up to 21 years - NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Corpus Christi, TexasAges Up to 50 years - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Houston, TexasAges 1–30 - NCT06023641RecruitingPhase 2
Liposomal irinotecan for children with rhabdomyosarcoma
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Fort Worth, TexasAges Up to 22 years - NCT06721689RecruitingPhase 1/Phase 2
PEEL-224 with chemo for pediatric solid tumors
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Houston, TexasAges 1–30 - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
Houston, TexasAges 2–18 - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Dallas, TexasAges 6 months–30 years - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25 - NCT05108298Recruiting
Study to improve cancer survey reporting for young adults
This study focuses on collecting better self-reported information (from questionnaires) from young adults with cancer. It may help improve how future cancer trials understand symptoms and quality-of-life needs.
Bryan, TexasAges 18–39 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Dallas, TexasAges Up to 30 years
Rhabdomyosarcoma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting rhabdomyosarcoma studies listed above.
- Texas Children's Hospital · 4 studies
- University of Texas Health Science Center at San Antonio · 3 studies
- University of Texas Southwestern Medical Center · 3 studies
- Baylor College of Medicine · 2 studies
- Cook Children's Medical Center · 2 studies
- Driscoll Children's Hospital · 2 studies
- Methodist Children's Hospital of South Texas · 2 studies
- The University of Texas MD Anderson Cancer Center · 2 studies
What taking part in a rhabdomyosarcoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Rhabdomyosarcoma trials in other states
Common questions
- Are there rhabdomyosarcoma clinical trials in Texas?
- Yes. We're currently tracking 12 recruiting rhabdomyosarcoma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a rhabdomyosarcoma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a rhabdomyosarcoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New rhabdomyosarcoma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.